Clinical trials: Stage III Prostate Adenocarcinoma
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men…
- Trial name
- NCT00002760
- Testing
- ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with…
- Trial name
- NCT00002703
- Testing
- high-LET heavy ion therapy, low-LET photon therapy
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Proton Radiation Oncology Group
Prostate Cancer
Selenium in Treating Patients With Prostate Cancer
RATIONALE: Selenium may prevent or slow the growth of prostate cancer. PURPOSE: This randomized phase II trial is studying how well selenium works in treating patients with prostate cancer.
- Trial name
- NCT00752739
- Testing
- selenium
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Arizona
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00258466
- Testing
- radiation therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003026
- Testing
- bicalutamide, flutamide, triptorelin
- Where
- 17 sites in Belgium, Israel and 5 more
- Volunteers
- 966 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Prostate Cancer
Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002511
- Testing
- low-LET photon therapy
- Where
- Belgium
- Volunteers
- 1,005 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as cyproterone acetate may stop the adrenal glands from making androgens. Sometimes the tumor may not need treatment until it progresses.
- Trial name
- NCT00363285
- Testing
- gonadotrophin releasing hormone, cyproterone acetate, quality-of-life assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 900 people
- Sponsor
- St. Bartholomew's Hospital
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03368547
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Hormone therapy combined with radiation therapy may be a more effective treatment for prostate cancer.
- Trial name
- NCT00769548
- Testing
- flutamide, goserelin acetate, low-LET photon therapy
- Volunteers
- 1,322 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer.
- Trial name
- NCT00305669
- Testing
- sargramostim, immunohistochemistry staining method, immunological diagnostic method
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003124
- Testing
- flutamide, leuprolide acetate, radiation therapy
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic